Facial Lipoatrophy following Systemic Lupus Erythematosus

2003 ◽  
Vol 7 (3) ◽  
pp. 232-235
Author(s):  
Audrey Dupéré ◽  
Yves Poulin

Background: Acquired partial lipodystrophy is a rare disorder. An association with systemic lupus erythematosus has been reported. In these cases, an immunologic basis is suggested by the presence of C3 nephritic factor and hypocomplementemia. Objective: The following report presents the case of a woman who developed a rapid loss of facial subcutaneous fat a few months after complete spontaneous resolution of cutaneous lesions of lupus. Conclusion: Absence of C3NeF in this case suggests that other immunological factors may be involved in the pathogenesis.

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Pamela Traisak ◽  
Shristi Basnyat ◽  
Hala Eid ◽  
Patrick Cronin ◽  
Halyna Kuzyshyn ◽  
...  

The clinical presentation of Systemic Lupus Erythematosus (SLE) is diverse and vasculitis can be a potential manifestation. Cutaneous lesions involving small vessels are the most frequent presentation. However, medium and large vessel vasculitis may present with life-threatening visceral manifestations. We present a unique case of pelvic vasculitis mimicking a pelvic mass as an initial presentation of SLE. There are case reports of systemic vasculitis involving the female genital tract with giant cell arteritis (GCA), polyarteritis nodosa (PAN), and granulomatous with polyangiitis and microscopic polyangiitis (GPA/MPA), among others, but only a few cases attributed to SLE. Awareness of this condition and a prompt diagnosis are warranted as this is a severe and potentially life-threatening condition.


2019 ◽  
Vol 106 (3) ◽  
pp. 291-301
Author(s):  
Martyna Skręta-Śliwińska ◽  
Anna Woźniacka ◽  
Ilona Kurnatowska ◽  
Maciej Goździk ◽  
Agnieszka Żebrowska

1999 ◽  
Vol 12 (4) ◽  
pp. 335-345
Author(s):  
Steven A. Scott

Systemic lupus erythematosus (SLE) is a chronic, multiple-organ system inflammatory disorder associated with immune system dysfunction. Autoantibodies are produced that react with self-antigens in cell membranes and nuclear and cytoplasmic constituents to produce tissue damage. Commonly observed clinical manifestations include arthritis, myalgia, fever, cutaneous lesions, cytopenia, and renal, CNS, and cardiopulmonary involvement. Minor manifestations can be managed with relatively nontoxic agents such as nonsteroidal anti-inflammatory drugs, topical corticosteroids, and antimalarials. Severe disease involving the kidneys, CNS, and cardiopulmonary systems requires the aggressive use of more toxic agents such as high-dose corticosteroids, azathioprine, and cyclophosphamide. Other supportive and ancillary therapies are also required to manage the complications frequently associated with SLE.


1992 ◽  
Vol 25 (1) ◽  
pp. 73-75 ◽  
Author(s):  
Nurimar C.F. Wanke ◽  
Claudia Melo ◽  
Viviam Balassiano

A child with systemic lupus erythematosus who has been treated with prednisone for three years, developed crusted scabies. Scrapings from lesions revealed Sarcoptes scabiei adult mites mad eggs. The patient died with septicemia and renal failure soon after starting topical 20% sulfur. A marked improvement was observed in the cutaneous lesions.


Sign in / Sign up

Export Citation Format

Share Document